● Recruiting

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Condition: Relapsed and Refractory Multiple Myeloma · Sponsor: University of Miami

PhasePhase 2

Planned participants33

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

This description comes directly from the study's public registry record.

Talk to the study team

Alanna Vossen · 305-243-7701 · avossen@miami.edu

Dickran Kazandjian, MD · dkazandjian@miami.edu

Always discuss trial participation with your own doctor first.

Locations (3)

University of Miami, Lennar Foundation Medical Center	Coral Gables, Florida, United States	Recruiting
University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach, Florida, United States	Recruiting
University of Miami, Sylvester Comprehensive Cancer Center	Miami, Florida, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05530421